Raphael J. Landovitz, MD, MSc
University of California Los Angeles
Professor of Medicine
Los Angeles, CA
Director, UCLA Center for Clinical AIDS Research & Education
University of California Los Angeles
Los Angeles, CA
Michael T. Laub, PhD
Massachusetts Institute of Technology
Salvador E. Luria Professor of Biology
Cambridge, MA
Dr Laub’s research currently focuses on phage-bacteria interactions with a particular emphasis on the antiphage defense mechanisms used by bacteria to defend themselves against phages and the counterdefense mechanisms employed by phages. We use a variety of genetic and computational tools to identify new antiphage defense systems in E. coli, B. subtilis, and S. aureus. The mechanistic basis of immunity provided by individual systems is pursued using a combination of genetics, biochemistry, cell biology, and structural approaches. The lab also examines the tempo, modes, and patterns of genome evolution in bacteria and phages that stems from their constant battle with each other.
(Updated July 18, 2024)
Clara Lehmann, MD
University Hospital Cologne
Senior Physician
Cologne, Germany
Deputy Coordinator HIV
German Center For Infectious Research (DZIF)
Cologne, Germany
Leah J. Leisch, MD
University of Alabama at Birmingham
Assistant Professor of Medicine
Birmingham, AL
Addiction Medicine Fellowship Program Director
Medical Director of Beacon Integrated Healthcare
Birmingham, AL
Jeffrey L. Lennox, MD
Emory University
Professor of Medicine and Associate Dean for Clinical Research
Atlanta, GA
Jian Li, PhD
Monash University
Professor of Microbiology
Melbourne, Australia
Dr Li is a Fellow of the Australian Academy of Science (AAS), the Australian Academy of Health and Medical Sciences (AAHMS), and the American Academy of Microbiology (AAM). He is also recognized as a Clarivate® Highly Cited Researcher in pharmacology and toxicology (2015-2017, 2022). His research focuses on antimicrobial chemotherapy (including phage pharmacology) and drug discovery, particularly in pharmacokinetics, pharmacodynamics, toxicodynamics, microbiology, systems pharmacology, and toxicity. Dr Li has 453 publications (including 10 book chapters) with 31,913 citations and an h-index of 85. He has delivered more than 110 invited conference talks, seminars and public lectures at universities, institutes, the Food and Drug Administration, and pharmaceutical companies internationally. His research led to the first scientifically-based dosing recommendations for colistin, which have been employed by the European Medicines Agency and improved clinical practice worldwide. Dr Li’s novel antibiotic drug QPX9003 has been developed from concept in his laboratory to clinical trials and licensed to Qpex Biopharma and Brii Biosciences. Since 2004 Dr Li has been awarded 63 grants (including 13 National Institutes of Health [NIH] R01) from various funding agencies and pharmaceutical companies. He is President of the International Society of Anti-Infective Pharmacology (2022-2024), Editor-in-Chief of the International Journal of Antimicrobial Agents and the first book on polymyxins (Springer Nature, 2019; >68,000 downloads), and an invited reviewer for approximately 200 international journals.
(Updated July 18, 2024)